Osteoporosis (OP) is a silently progressing metabolic bone disease. It is estimated to affect 200 million women worldwide – approximately one-tenth of women aged 60, one-fifth of women aged 70, two-fifths of women aged 80 and two-thirds of women aged 90 1. It is widely prevalent in Indian population as well 2. OP leads to loss of bone mass resulting in fractures after minor trauma, especially of spinal vertebrae, the bones of the forearm and hip. Globally, more than 8.9 million fractures every year occurs secondary to OP 3 and a considerable cause of morbidity and mortality 4. Studies have shown that post menopausal women with a positive family history, and who have low intake of calcium and Vitamin D in diet are at the highest risk 5. There is exaggerated bone loss as compared to new bone formation in OP. Therefore, measures most commonly applied for OP management are- regular weight bearing exercises, oral calcium and Vitamin D (Cholecalciferol) supplementation and drugs that decrease osteoclastic bone resorption like bisphosphonates (risedronate, alendronate), Selective Estrogen Receptor Modulators (Raloxifene) and Calcitonin 6. Teriperatide, a congener of parathyroid hormone has been recently introduced for OP treatment and it has been shown to increase new bone formation 7. However, much less is known about the effectiveness of Teriperatide considering its high cost in the Indian population.Despite availability of various treatments for OP it has a profound negative impact on the Quality of Life (QoL) as pointed out by numerous studies 8. Fractures have a negative impact on self-esteem, body image, and mood, which may lead to psychological consequences. Thus, the psychosocial suffering of the patient must also be evaluated. Furthermore, there is a paucity of Indian studies in this field. Hence the QoL evaluation of post menopausal patients suffering from OP becomes imperative.